Portola Pharmaceuticals   Print Page    Close Window

Portola Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended September 30, 2018, and provide a general business overview on Wednesday, November 7, 2018, at 4:30 p.m. ET (1:30 p.m. PT).

Conference Call Details
The live conference call on Wednesday, November 7, 2018, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 3387315. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.

     
Investor Contact:   Media Contact:
Cara Miller   Patrick Ryan
Portola Pharmaceuticals   Pure Communications
ir@portola.com   pryan@purecommunications.com

Portola Pharmaceuticals Logo

Portola Pharmaceuticals, Inc.